404 related articles for article (PubMed ID: 8158700)
21. Absence of retinoblastoma protein expression in primary non-small cell lung carcinomas.
Xu HJ; Hu SX; Cagle PT; Moore GE; Benedict WF
Cancer Res; 1991 May; 51(10):2735-9. PubMed ID: 1850661
[TBL] [Abstract][Full Text] [Related]
22. [Expression of alpha-tubulin and MDR1 and their correlation with the biological features of non-small cell lung carcinoma].
Chen QY; Jiang ZY; Wu LJ; Zhang BY; Lu GH; Zhou JY
Zhonghua Zhong Liu Za Zhi; 2010 Apr; 32(4):278-82. PubMed ID: 20510079
[TBL] [Abstract][Full Text] [Related]
23. Significance of P53 and Rb protein expression in surgically treated non-small cell lung cancers.
Lee YC; Chang YL; Luh SP; Lee JM; Chen JS
Ann Thorac Surg; 1999 Aug; 68(2):343-7; discussion 348. PubMed ID: 10475393
[TBL] [Abstract][Full Text] [Related]
24. Expression of p53 and RB proteins in squamous cell carcinoma of the esophagus: their relationship with clinicopathologic characteristics.
Hashimoto N; Tachibana M; Dhar DK; Yoshimura H; Nagasue N
Ann Surg Oncol; 1999; 6(5):489-94. PubMed ID: 10458688
[TBL] [Abstract][Full Text] [Related]
25. Altered expression of the retinoblastoma gene product: prognostic indicator in bladder cancer.
Cordon-Cardo C; Wartinger D; Petrylak D; Dalbagni G; Fair WR; Fuks Z; Reuter VE
J Natl Cancer Inst; 1992 Aug; 84(16):1251-6. PubMed ID: 1640484
[TBL] [Abstract][Full Text] [Related]
26. Prognostic prediction of the immunohistochemical expression of p53 and p16 in resected non-small cell lung cancer.
Cheng YL; Lee SC; Harn HJ; Chen CJ; Chang YC; Chen JC; Yu CP
Eur J Cardiothorac Surg; 2003 Feb; 23(2):221-8. PubMed ID: 12559346
[TBL] [Abstract][Full Text] [Related]
27. Retinoblastoma protein expression and radiation response in muscle-invasive bladder cancer.
Pollack A; Czerniak B; Zagars GK; Hu SX; Wu CS; Dinney CP; Chyle V; Benedict WF
Int J Radiat Oncol Biol Phys; 1997 Oct; 39(3):687-95. PubMed ID: 9336151
[TBL] [Abstract][Full Text] [Related]
28. Correlation of abnormal RB, p16ink4a, and p53 expression with 3p loss of heterozygosity, other genetic abnormalities, and clinical features in 103 primary non-small cell lung cancers.
Geradts J; Fong KM; Zimmerman PV; Maynard R; Minna JD
Clin Cancer Res; 1999 Apr; 5(4):791-800. PubMed ID: 10213214
[TBL] [Abstract][Full Text] [Related]
29. Mutations in exon 7 and 8 of p53 as poor prognostic factors in patients with non-small cell lung cancer.
Huang C; Taki T; Adachi M; Konishi T; Higashiyama M; Miyake M
Oncogene; 1998 May; 16(19):2469-77. PubMed ID: 9627113
[TBL] [Abstract][Full Text] [Related]
30. Prognostic value of the expression of p53, bcl-2, and bax oncoproteins, and neovascularization in patients with radically resected non-small-cell lung cancer.
Apolinario RM; van der Valk P; de Jong JS; Deville W; van Ark-Otte J; Dingemans AM; van Mourik JC; Postmus PE; Pinedo HM; Giaccone G
J Clin Oncol; 1997 Jun; 15(6):2456-66. PubMed ID: 9196162
[TBL] [Abstract][Full Text] [Related]
31. Prognostic implications of neuroendocrine differentiation and hormone production in patients with Stage I nonsmall cell lung carcinoma.
Pelosi G; Pasini F; Sonzogni A; Maffini F; Maisonneuve P; Iannucci A; Terzi A; De Manzoni G; Bresaola E; Viale G
Cancer; 2003 May; 97(10):2487-97. PubMed ID: 12733148
[TBL] [Abstract][Full Text] [Related]
32. Prognostic implications of cell cycle-related proteins in primary resectable pathologic N2 nonsmall cell lung cancer.
Mohamed S; Yasufuku K; Hiroshima K; Nakajima T; Yoshida S; Suzuki M; Sekine Y; Shibuya K; Iizasa T; Farouk A; Fujisawa T
Cancer; 2007 Jun; 109(12):2506-14. PubMed ID: 17487846
[TBL] [Abstract][Full Text] [Related]
33. Loss of pRb2/p130 expression is associated with unfavorable clinical outcome in lung cancer.
Caputi M; Groeger AM; Esposito V; De Luca A; Masciullo V; Mancini A; Baldi F; Wolner E; Giordano A
Clin Cancer Res; 2002 Dec; 8(12):3850-6. PubMed ID: 12473599
[TBL] [Abstract][Full Text] [Related]
34. Mutations of the p53 gene as a predictor of poor prognosis in patients with non-small-cell lung cancer.
Mitsudomi T; Oyama T; Kusano T; Osaki T; Nakanishi R; Shirakusa T
J Natl Cancer Inst; 1993 Dec; 85(24):2018-23. PubMed ID: 8246288
[TBL] [Abstract][Full Text] [Related]
35. Clinical significance of SOX9 in human non-small cell lung cancer progression and overall patient survival.
Zhou CH; Ye LP; Ye SX; Li Y; Zhang XY; Xu XY; Gong LY
J Exp Clin Cancer Res; 2012 Mar; 31(1):18. PubMed ID: 22385677
[TBL] [Abstract][Full Text] [Related]
36. The interactive effect of Ras, HER2, P53 and Bcl-2 expression in predicting the survival of non-small cell lung cancer patients.
Kim YC; Park KO; Kern JA; Park CS; Lim SC; Jang AS; Yang JB
Lung Cancer; 1998 Dec; 22(3):181-90. PubMed ID: 10048471
[TBL] [Abstract][Full Text] [Related]
37. [Correlation analysis among expression of ERCC-1, metallothionein, p53 and platinum resistance and prognosis in advanced non-small cell lung cancer].
Huang PY; Liang XM; Lin SX; Luo RZ; Hou JH; Zhang L
Ai Zheng; 2004 Jul; 23(7):845-50. PubMed ID: 15248926
[TBL] [Abstract][Full Text] [Related]
38. Prognostic molecular markers in non-small cell lung cancer.
Nikliński J; Niklińska W; Laudanski J; Chyczewska E; Chyczewski L
Lung Cancer; 2001 Dec; 34 Suppl 2():S53-8. PubMed ID: 11720742
[TBL] [Abstract][Full Text] [Related]
39. Prognostic significance of p21waf1, cyclin D1 and retinoblastoma expression detected by immunohistochemistry in non-small cell lung cancer.
Saitoh G; Sugio K; Ishida T; Sugimachi K
Oncol Rep; 2001; 8(4):737-43. PubMed ID: 11410775
[TBL] [Abstract][Full Text] [Related]
40. Altered expression of the cell cycle regulatory molecules pRb, p53 and MDM2 exert a synergetic effect on tumor growth and chromosomal instability in non-small cell lung carcinomas (NSCLCs).
Gorgoulis VG; Zacharatos P; Kotsinas A; Mariatos G; Liloglou T; Vogiatzi T; Foukas P; Rassidakis G; Garinis G; Ioannides T; Zoumpourlis V; Bramis J; Michail PO; Asimacopoulos PJ; Field JK; Kittas C
Mol Med; 2000 Mar; 6(3):208-37. PubMed ID: 10965496
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
